Hannah Chang

Hannah Chang, M.D., Ph.D. is a prominent figure in the healthcare venture capital industry, combining expertise as a physician, scientist, and investor. She currently serves as the Managing Director at Wu Capital (双湖资本), where she focuses on early-stage biopharmaceutical venture capital investments from the firm's San Francisco office.2

Education and Background

Dr. Chang has an impressive educational background:

• M.D. from Harvard Medical School
• Ph.D. in Biophysics from Harvard University
• B.A. in Chemistry from Princeton University (Summa cum laude)3

She completed clinical training in internal medicine at Beth Israel Deaconess Medical Center and ophthalmology at Massachusetts Eye and Ear Infirmary.1

Professional Experience

• Managing Director at Wu Capital (July 2017 - Present): Leading healthcare venture capital strategy, investing in innovative biotechnology companies.3
• Associate at 5AM Ventures (June 2014 - July 2017): Helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as Board Observer for several companies.3
• Project Leader at The Boston Consulting Group (January 2012 - May 2014): Member of the Healthcare Practice.3

Board Positions

Dr. Chang holds board positions in several companies, including:

• Ray Therapeutics, Inc.
• Nuvig Therapeutics Inc.
• Korro Bio, Inc.
• IniPharm Pharmaceuticals3

She has also served as a board observer for companies like PACT Pharma, Perfuse Therapeutics, and Akouos.3

Investment Portfolio

Her representative investments include:

• Semma Therapeutics (acquired by Vertex Pharmaceuticals)
• Akouos (NASDAQ: AKUS, acquired by Eli Lilly)
• Korro Bio (NASDAQ: KRRO)
• Inipharm
• Gemini Therapeutics12

Dr. Chang's expertise in life sciences venture capital, combined with her medical and scientific background, positions her as a valuable asset in identifying and supporting innovative biotechnology companies with transformative therapeutic potential.1